The authors reply

We thank Huang and Yu1 for their clarification on the role of daclatasvir and asunaprevir in hepatitis C virus (HCV) –infected patients with chronic kidney disease. As they note, this regimen is most appropriate for patients infected with HCV genotype 1b as it is less efficacious in HCV genotype 1a.2 This postmarketing study, published after the last update in May 2017 of the Kidney Disease: Improving Global Out comes evidence review search, does provide useful additional information on the use of this regimen.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Letter to the Editor Source Type: research